论文部分内容阅读
麦迪霉素(Medemycin 或 Mydecamycin)是由放线菌(Streptomyces mycarofacieus)所产生的一种大环内酯族抗菌素。1971年由日本首先发现,并应用于临床。本品的抗菌作用与柱晶白霉素相似,对革兰氏阳性细菌和革兰氏阴性球菌有良好抗菌作用,毒性低微,临床疗效比较满意。中国医学科学院药物研究所和苏州第二制药厂于1974年3月自广东省大埔县土壤中分离到麦迪霉素产生菌,定名为生米加链霉菌1748。本品1976年试制成功后已应用于临床。现将上海地区麦迪霉素的临床应用结果报道如
Medemycin or Mydecamycin is a macrolide antibiotic produced by Streptomyces mycarofacieus. First discovered by Japan in 1971, and used in clinical. The antibacterial activity of this product is similar to that of leucopenicillam. It has good antibacterial activity against Gram-positive bacteria and Gram-negative cocci, with low toxicity and satisfactory clinical efficacy. Institute of Materia Medica, Chinese Academy of Medical Sciences and Suzhou No. 2 Pharmaceutical Factory in March 1974 from the soil in Tai Po County, Guangdong Province isolated midecamycin-producing bacteria, known as raw rice plus Streptomyces 1748. This product has been successfully applied in clinical trials in 1976. Now the clinical application of midecamycin in Shanghai reported results